Author

A. B. Hartono

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Ghosh· 1 shared A. J. W. Lui· 1 shared C. A. Pratilas· 1 shared C. E. Jackson· 1 shared D. Cardin· 1 shared D. T. Truong· 1 shared E. de Stanchina· 1 shared E. Gladstone· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Ghosh

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Enzalutamide Induces Cytotoxicity in Desmoplastic Small Round Cell Tumor Independent of the Androgen Receptor

J. W. Magrath, I. N. Goldberg, D. T. Truong, A. B. Hartono, S. S. Sampath, C. E. Jackson, A. Ghosh, D. Cardin, H. Zhang, J. Ludwig, S. Lee

The paper shows enzalutamide reduces DSRCT growth independently of AR, challenging the hypothesis that AR drives male predominance in this cancer.

bioRxiv · Nov 6, 2023Cancer Biology

Establishment of multiple novel patient-derived models of desmoplastic small round cell tumor enabling functional characterization of ERBB pathway signaling and pre-clinical evaluation of a novel targeted therapy approach

R. S. Smith, I. Odintsov, Z. Liu, T. Hayashi, A. J. W. Lui, M. Vojnic, Y. Suehara, M. S. Mattar, J. Hmeljak, H. A. Ramirez, M. Shaw, G. Bui, A. B. Hartono, E. Gladstone, H. Magnan, , R. Somwar

This study develops new DSRCT models and shows that targeting the ERBB pathway with EGFR inhibitors reduces tumor growth in preclinical models.

bioRxiv · Sep 22, 2020 · PreprintCancer Biology